【康宁杰瑞制药-B(09966.HK)：KN052治疗晚期实体瘤的两项临床试验获国家药监局IND批准】智通财经APP讯，康宁杰瑞制药-B(09966.HK)发布公告，该公司已于近日从国家药监局收到两项IND批准，详情如下：

【康宁杰瑞制药-B(09966.HK)：KN052治疗晚期实体瘤的两项临床试验获国家药监局IND批准】智通财经APP讯，康宁杰瑞制药-B(09966.HK)发布公告，该公司已于近日从国家药监局收到两项IND批准，详情如下：

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.